), a prominent player in the field of diagnostic testing, has
expanded its portfolio with a new laboratory assay named TERC test
to help physicians recognize molecular changes to cervical cells
that increase the probability of cervical cancer in women.
QUEST DIAGNOSTC (DGX): Free Stock Analysis
LABORATORY CP (LH): Free Stock Analysis Report
To read this article on Zacks.com click here.
As cervical cancer fails to produce symptoms in the initial stages,
this test is expected to play a vital role in the detection of
pre-cervical cellular abnormalities among thousands of women with
the risk of malignancy each year.
According to Quest Diagnostics, when standard screening tests like
Papanicolaou (Pap) and human papillomavirus (HPV) fail to provide
clear results about the cervical cancer risk, its TERC test will
enable physicians to detect women who display characteristics of a
cancerous state, unless treated.
The test will examine the abnormalities of telomerase RNA component
(TERC) gene based on advanced scientific knowledge on molecular
changes that turn cervical dysplasia into malignancy. The company
believes that this test, which is designed as an addition to Pap
and HPV tests, will act as a second opinion for doctors to confirm
malignancy in the initial stage.
To develop the TERC test for cervical cancer, Quest Diagnostics
earlier acquired a nonexclusive patent license for human TERC gene
marker from the National Institutes of Health (NIH). TERC result
will help in classifying risks in abnormal Pap tests prior to
Women with high risk results may benefit from additional cervical
biopsies at colposcopy and more aggressive observation and
treatment, while women with low-risk results may undergo lesser
With cervical cancer a major cause of death in women in the U.S.,
we expect this TERC test to mark a definite improvement over
traditional methods, leading to better treatment from faster
detection. Therefore this test should strengthen Quest Diagnostics
portfolio of molecular testing.
Quest Diagnostics has been working continuously on expanding its
portfolio. In early 2012, the company started offering testing
services to identify E6/E7 messenger RNA to help detect women
infected with HPV who may have a significantly increased risk of
Other significant tests that were launched over the recent past
include a thyroid test to help physicians determine whether a
thyroid gland is cancerous and requires surgical removal. Also, the
company introduced c. difficile test and an advanced renal
transplant monitoring test to detect rejection in kidney-transplant
This test enables physicians to adjust therapy based on an
individual's genetic makeup. All these tests not only improve
patient care but also reduce the high costs associated with
Quest Diagnostics is currently focusing on latent areas such as
drugs-of-abuse testing, gene-based, esoteric testing for cancer,
cardiovascular disease, infectious disease and neurological
disorders. The company has been witnessing stronger demand for
these tests than routine tests.
In order to bolster this specialized niche, Quest Diagnostics has
engaged in accretive acquisitions such as Athena and Celera. This
apart, we are encouraged by Quest's efforts to improve its sales
effectiveness and strengthen its relationship with health plans and
However, the company continues to witness challenges with respect
to physician office visits, which remains soft. Moreover, the
competitive landscape is tough with the presence of
Laboratory Corporation of America Holdings
). LabCorp is also targeting the esoteric testing space and has
acquired Genzyme Genetics to meet its objective.
We currently have a Neutral recommendation on Quest Diagnostics
over the long term. The stock retains a short-term Zacks #3 Rank
(We are reissuing this article to correct a mistake. The
original article, issued earlier today, September 5, 2012, should
no longer be relied upon.)